Alkem Labs Slapped Rs 2.34 Cr GST Demand in Goa

Published On 2026-01-24 18:03 GMT | Update On 2026-01-24 18:03 GMT

New Delhi: Alkem Laboratories Limited has received a demand order from the Additional Commissioner of Central Goods and Services Tax (CGST), Goa, under the Goods and Services Tax Act, 2017, raising a tax demand of Rs 2.34 crore along with an equivalent amount towards interest and penalty.

In a regulatory disclosure, the pharmaceutical company stated that the order has been issued for its Goa GSTIN for the period spanning 2019–20 to 2022–23. The total GST demanded amounts to ₹2,34,61,952, with an additional ₹2,34,61,952 levied as applicable interest and penalty under the provisions of the IGST Act, 2017, CGST Act, 2017 and SGST Act, 2017.

The company clarified that the order was received on January 21, 2026, and the demand primarily relates to allegations of excess availment of Input Tax Credit (ITC). Alkem Laboratories has stated that it does not agree with the findings of the tax authority and plans to contest the demand.

Also Read: Alkem Labs Receives Rs 9.72 Lakh GST Demand for FY 2021-22

According to the disclosure, Alkem is currently in the process of taking appropriate actions, including filing an appeal against the order before the relevant appellate authority. The company has emphasized that it will pursue all available legal remedies to challenge the GST demand.

Alkem Laboratories further noted that the demand order does not have any material impact on its financial position, operations, or other business activities. The company reassured investors that the issue is not expected to adversely affect its ongoing operations.

Also Read: Alkem Foundation, IIT Bombay collaborate to set up advanced research centre for immunotherapeutics, regenerative medicines

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Parthika Patel

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Alkem Labs Slapped Rs 2.34 Cr GST Demand in Goa

Similar News

USFDA Closes Inspection at Zydus Ankleshwar Unit-2 With Three Observations

Akums Drugs Secures EU-GMP Certification for Two Haridwar Plants

Abbott's Phensedyl Supply Chain Under Scanner After Ghaziabad Seizure, Codeine Diversion Probe Widens

Cipla Reappoints P R Ramesh as Independent Director for Second Term Till 2031

No Monopoly Over Alphabets: Delhi HC Rejects Alkem's 'A TO Z' Trademark Claim

CDSCO Clears Over 100 rDNA Drugs and Biologics Between 2020-25, Boosting Access to Advanced Therapies

AbbVie Loses India Patent Bid for Cancer Drug Venetoclax, Generics Set to Enter Market